<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To identify patients who developed secondary clonal cytogenetic aberrations (CCA) following therapy for <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo> (APL), we retrospectively analyzed cytogenetic results from 123 patients diagnosed with APL between 1995 and 2007, who had ongoing cytogenetic analysis undertaken in our laboratory </plain></SENT>
<SENT sid="1" pm="."><plain>During follow-up for APL we identified 12 patients (9.8%) who developed CCA, not detected at diagnosis of APL and unrelated to their original APL karyotype </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had received <z:hpo ids='HP_0000001'>all</z:hpo>-trans <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (ATRA) and chemotherapy and were in complete remission for APL when secondary CCA were identified </plain></SENT>
<SENT sid="3" pm="."><plain>The median latency period between diagnosis of APL and emergence of secondary CCA was 27.5 months (range: 2-54 months) </plain></SENT>
<SENT sid="4" pm="."><plain>To date, four patients with CCA have been diagnosed with therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>)/<z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), giving a median t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> free survival of 78 months, with follow-up ranging between 20 and 136 months from APL diagnosis </plain></SENT>
<SENT sid="5" pm="."><plain>Three patients have died: two patients died of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and another developed relapsed APL with persistence of his secondary clone but no diagnosis of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and died from transplant-related complications </plain></SENT>
<SENT sid="6" pm="."><plain>Two patients are alive with t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Seven patients with CCA are alive with no morphological evidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> at the time of their last known follow-up; thus median survival has not been reached </plain></SENT>
<SENT sid="8" pm="."><plain>The appearance of these abnormalities in the absence of morphological evidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in the majority of patients is unusual, and highlights the importance of continued cytogenetic follow-up in these patients </plain></SENT>
<SENT sid="9" pm="."><plain>Am </plain></SENT>
<SENT sid="10" pm="."><plain>J </plain></SENT>
<SENT sid="11" pm="."><plain>Hematol., 2009 </plain></SENT>
<SENT sid="12" pm="."><plain>(c) 2009 Wiley-Liss, Inc </plain></SENT>
</text></document>